NMR-based metabolomics approach to target biomarkers for human prostate cancer (Q36841884)

16 August 2017

1 reference

title

NMR-based metabolomics approach to target biomarkers for human prostate cancer (English)

1 reference

16 August 2017

0 references

1 reference

nmr-based metabolomics

1 reference

1 reference

Kate W Jordan

1 reference

16 August 2017

Leo L Cheng

series ordinal

1 reference

16 August 2017

publication date

1 June 2007

1 reference

Expert Review of Proteomics

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

389-400

1 reference

16 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Functional Genomics: all the king's horses and all the king's men can put Humpty together again

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Choline metabolism in cancer: implications for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Sickle cell anemia, a molecular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

HMDB: the Human Metabolome Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Metabolomics: current technologies and future trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Metabolomics – the link between genotypes and phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Metabonomic analysis of mouse urine by liquid-chromatography-time of flight mass spectrometry (LC-TOFMS): detection of strain, diurnal and gender differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Oncogenic alterations of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Prostate cancer incidence and mortality in the United States and the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

MR imaging and MR spectroscopy in prostate cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Imaging of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Proton HR‐MAS spectroscopy and quantitative pathologic analysis of MRI/3D‐MRSI‐targeted postsurgical prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

Removal of Dipolar Broadening of Nuclear Magnetic Resonance Spectra of Solids by Specimen Rotation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.4.3.389

21 January 2018

Identifiers

DOI

10.1586/14789450.4.3.389

1 reference

16 August 2017

1 reference